|
Post by hellodolly on Feb 28, 2019 11:54:04 GMT -5
Here's a slide I added to the presentation a little while back with info from their 10K
SlidesWhat stuck out to me when Mike was talking about the results of the clinical trails for this product, they discovered that the efficacy was "three (3) fold" [Mike's words] more uptake, compared to use with their nebulizer. I'm going to guess that the patients used the dreamboat for the trials.
|
|
|
Post by sportsrancho on Mar 4, 2019 6:19:57 GMT -5
|
|
|
Post by peppy on Mar 4, 2019 7:41:28 GMT -5
Here's a slide I added to the presentation a little while back with info from their 10K
SlidesWhat stuck out to me when Mike was talking about the results of the clinical trails for this product, they discovered that the efficacy was "three (3) fold" [Mike's words] more uptake, compared to use with their nebulizer. I'm going to guess that the patients used the dreamboat for the trials.
|
|
|
Post by harryx1 on Mar 5, 2019 15:55:14 GMT -5
Here's a video for Tyvaso (found by Thundersnow on ST) that shows what a patient currently uses for treatment. I'm glad they have something that works but I agree that TreT will be a significant lifestyle improvement as UTHR says.
|
|
|
Post by harryx1 on Mar 6, 2019 11:10:58 GMT -5
I think this might be the most Impressions for a tweet I've had in less than 24 hours, wow!
|
|
|
Post by peppy on Mar 6, 2019 11:22:56 GMT -5
Here's a video for Tyvaso (found by Thundersnow on ST) that shows what a patient currently uses for treatment. I'm glad they have something that works but I agree that TreT will be a significant lifestyle improvement as UTHR says. treatment very time consuming. All the parts she assembled were clean and dry. A mist, H20 used, the parts would need to be cleaned and dried daily. She uses the assembled tubing system four times a day, it lasts 4 hours.
|
|
|
Post by therealisaching on Mar 11, 2019 11:21:00 GMT -5
|
|
|
Post by therealisaching on Mar 11, 2019 14:59:45 GMT -5
slides are up. mnkd is going to be discussed
|
|
|
Post by therealisaching on Mar 11, 2019 16:10:50 GMT -5
My quick notes. The CFO presented & spend approx 2 minutes of a 30 minute presentation on TreT of which there was one dedicated slide. Not insignificant in my view. My quick notes are as follows:
In 2018 we entered into a worldwide exclusive license in collaboration agreement with Mannkind Corp for development and commercialization of a dry powder formulation of trepostinal called techonosphere trepostinal or Tre T. Simply put TreT incorporates powder formulated formulation technology currently used by mankind products Afrezza and also reduces the burden of trepostinal inhation from a nebulizer down to a small device. If the FDA approved TreT we believe this new inhalation therapy will provide substantial lifestyle benefits because it will be less time consuming and easier to administer and 2 will be mobile and more convenient. We plan to commence a clinical study called Breeze during the 1st half of 2019 to evaluate the switching of PAH patients from Tyvaso to TreT as well as a pharmacokinetic study in healthy volunteers we also plan to develop TreT for patients with PAH ILD and COPD and in addition the IP protection for TreT and the current devices include multiple patent families covering US and other major markets with expiration date the range from the mid 2020's to the mid 2030s
|
|
|
Post by sportsrancho on Mar 11, 2019 16:14:42 GMT -5
Breeze👍🏻
|
|
|
Post by harryx1 on Mar 11, 2019 16:16:45 GMT -5
|
|
|
Post by mytakeonit on Mar 11, 2019 16:34:15 GMT -5
Perfect name because it'll be a Breeze to pass this clinical study.
|
|
|
Post by peppy on Mar 11, 2019 16:44:16 GMT -5
Perfect name because it'll be a Breeze to pass this clinical study. Going from Ambition to Breeze. 42 meters = 137.795 feet. How many feet to the end of your driveway?
|
|
|
Post by wsulylecoug on Mar 11, 2019 16:47:46 GMT -5
My quick notes. The CFO presented & spend approx 2 minutes of a 30 minute presentation on TreT of which there was one dedicated slide. Not insignificant in my view. My quick notes are as follows: In 2018 we entered into a worldwide exclusive license in collaboration agreement with Mannkind Corp for development and commercialization of a dry powder formulation of trepostinal called techonosphere trepostinal or Tre T. Simply put TreT incorporates powder formulated formulation technology currently used by mankind products Afrezza and also reduces the burden of trepostinal inhation from a nebulizer down to a small device. If the FDA approved TreT we believe this new inhalation therapy will provide substantial lifestyle benefits because it will be less time consuming and easier to administer and 2 will be mobile and more convenient. We plan to commence a clinical study called Breeze during the 1st half of 2019 to evaluate the switching of PAH patients from Tyvaso to TreT as well as a form of connect pharmacokinetic study in healthy volunteers we also plan to develop TreT for patients with PAH ILD and COPD and in addition the IP protection for TreT and the current devices include multiple patent families covering US and other major markets with expiration date the range from the mid 2020's to the mid 2030s Turning to slide 12 (11:45 in presentation)...Tyvaso Therapeutic Platform. "Where we are counting on this platform to double United Therapeutics in size in the next few years and then again in the 2020's". That was my favorite line. Three Phase 3 trials, BEAT INCREASE & PERFECT, either fully enrolled or quickly enrolling will feed the Tyvaso Platform. BREEZE will be the proving grounds for TreT to take over that platform. SO likes to tout the Ralinepag licensing agreement, but I'll take our agreement in the long run anytime! Add the undisclosed compound and UT is counting on little ole MNKD to support a more than doubling of the company in the next few years. Did I hear that right?
|
|
|
Post by sportsrancho on Mar 11, 2019 16:54:36 GMT -5
|
|